HealthInsight

healthinsight.org

HealthInsight is a nonprofit, community-based health care consulting organization dedicated to improving health and health care. HealthInsight has more than 40 years of experience assisting front-line providers and engaging health care stakeholders. Our services improve outcomes and deliver measureable results that directly influence the care delivered to millions of people.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMABCINE EXPANDS PARTNERSHIP WITH SAMSUNG BIOLOGICS FOR PMC-403

PharmAbcine Inc. | September 21, 2020

news image

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders. Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support. PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibo...

Read More

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

news image

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More

MEDICAL

YESCARTA® RECEIVES U.S. FDA APPROVAL AS FIRST CAR T-CELL THERAPY FOR INITIAL TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

LBCL | April 04, 2022

news image

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard ratio 0.398; P< 0.0001) over the cur...

Read More

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

news image

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More
news image

PHARMABCINE EXPANDS PARTNERSHIP WITH SAMSUNG BIOLOGICS FOR PMC-403

PharmAbcine Inc. | September 21, 2020

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders. Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support. PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibo...

Read More
news image

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More
news image

MEDICAL

YESCARTA® RECEIVES U.S. FDA APPROVAL AS FIRST CAR T-CELL THERAPY FOR INITIAL TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

LBCL | April 04, 2022

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard ratio 0.398; P< 0.0001) over the cur...

Read More
news image

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More